AzTrials
AzTrials

Food HypersensitivityNCT03693456

Food Allergy Diagnostic Test Response to Previous Oral Challenge Response

A study testing Conjunctival Allergen Challenge in people with Food Hypersensitivity, run by ORA, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to compare the ocular response to CAC (using food allergen sensitive patients) to the systemic response of a previously performed oral food allergen challenge in the same subjects. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Food Hypersensitivity
What is being tested?
Conjunctival Allergen Challenge
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
19 participants
Where
1 siteUnited States
Study dates
May 2016to Oct 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Be male or female of any race, at least 5 years of age with documented food challenge in the past 12 months;
  • Have provided verbal and written informed consent. If under 18, a parent/guardian must provide consent for the subject;
  • Negative pregnancy test for women of childbearing potential;
  • Be willing and able to follow instructions, including participation in study assessments, and can be present for the required study visits for the duration of the study;

Who cannot join

  • Be a woman who is pregnant or nursing an infant;
  • Be unable to discontinue short-acting antihistamines for three days or long-acting antihistamines for five to seven days (depending on half-life) prior to CAC;
  • Have asthma that has evolved and now fulfills any of the criteria defined as follows:
  • uncontrolled persistent asthma by National Asthma Education and Prevention Program Asthma guidelines (2007) or by Global Initiative for Asthma (2011) or being treated with combination therapy of medium dose inhaled corticosteroid with a long acting inhaled β2-agonists.
  • at least two systemic corticosteroid courses for asthma in the past year or one oral corticosteroid course for asthma in the past three months.
  • prior intubation for asthma in the past year;
Show all 13Show fewer
  • Be receiving β-blocking agents, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant therapy;
  • Be receiving or planning to receive anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or any biologic immunomodulatory therapy;
  • Be receiving or planning to receive any type of immunotherapy to any food (e.g. oral immunotherapy, sublingual immunotherapy, specific oral tolerance induction) during their participation in the study;
  • Be receiving or planning to receive any aeroallergen immunotherapy during their participation in the study;
  • Be suffering from generalized dermatologic disease (e.g. severe atopic dermatitis, uncontrolled generalized eczema, ichthyosis vulgaris);
  • Have any new disorder in which epinephrine is contraindicated such as coronary artery disease, uncontrolled hypertension, or serious ventricular arrhythmias;
  • Have experienced severe anaphylaxis resulting in emergency hospitalization;

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Allergy, Asthma & Immunology Relief (AAIR) of Charlotte

    Charlotte, North Carolina, 28204

Other trials in United States

About this study

Official title: An Exploratory Pilot Study Evaluating the Correlation Between Conjunctival Allergen Challenge (CAC) Response to Dissolved Food Allergen and Previously Performed Oral Escalating Dose Food Challenge Response

The objective of this study is to compare the ocular response to CAC (using food allergen sensitive patients) to the systemic response of a previously performed oral food allergen challenge in the same subjects. This study will investigate the potential utility of CAC as a predictive tool for identifying patient response to food allergen challenge and maximum tolerated dose.

Read the detailed description

Patients usually discover they have food allergies after consuming a given food and experiencing a subsequent allergic reaction. The majority of patients (75%) will then consult a food allergist for formal diagnosis and treatment information.1 With respect to patient quality of life, there is tremendous benefit in having a confirmed diagnosis of food allergy as often patients are unsure of the source of their reaction outside the office. Allergists will conduct Skin Prick Test (SPT) and assess serum specific IgE levels to screen for specific food protein sensitivities. However, a positive response in SPT and specific IgE will confirm only sensitivity, and in more than 70% of cases patients that respond positively to SPT and specific IgE testing will NOT manifest an allergic response to food consumption.2 To address this issue, most food allergists will recommend an oral food challenge in a controlled setting to confirm the allergic response from consuming the suspected foods. The oral food challenge (OFC) consists of consuming escalating levels of the suspect food, (usually mixed in applesauce or controlled baked goods), until either a reaction manifests or until the challenge is complete with no reaction. The food challenge process poses significant risk to the patient. In 5% of cases, the patient experiences a severe allergic response which requires the use of epinephrine.2,3 These responses typically consist of severe reactions in GI or respiratory and arise from challenging patients with higher doses of food allergen then is necessary to prove a mild allergic response. The reason an allergist would give an increased dose that the patient reacts to with severity results from misdiagnosing the mild forms of the reaction during the titrated challenge. It is this shortcoming in diagnosis that could be addressed by identifying high-risk patient populations through conjunctival allergen challenge and through the development of additional objective diagnostic endpoints.

We hypothesize that conjunctival allergen challenge (CAC) may be able to predict which patients are likely to experience an adverse event during a food allergen challenge. The appearance of severe ocular response following CAC (level II on a 0-2 Scale) has been shown to correlate well with a positive food response during escalating food challenge, and represented a better predictor of food allergen than skin test and serum specific IgE combined.4 We hypothesize that the severity of the ocular response to CAC titration, or the appearance of related non-ocular signs and symptoms of systemic response to CAC (itchy palate, wheezing, FEV1 reduction) could correlate with the likelihood of experiencing a severe adverse event during food challenge. In order to mitigate the occurrence of severe adverse events during food challenge, and to determine if the CAC response can serve as a useful tool for informing the clinician of anticipated patient response patterns to oral food allergen challenge, we will perform CAC titration on a population of food allergy patients that previously underwent oral food escalating challenge. Any patterns in CAC response will be compared to historical food allergen reactivity and occurrence of severe adverse responses to evaluate the potential of the CAC as a predictive tool that could add value to the oral food challenge model.

Being tested
Conjunctival Allergen Challenge
Medical subject headings
Food Hypersensitivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Conjunctival Allergen ChallengeOther

    Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.

Study groups in NCT03693456
Study groupRoleWhat they receive
Responders Without EpinephrineExperimentalSubjects experienced a positive response during previous oral food challenge without a severe adverse event and did not require epinephrine. Will be subjected to a conjunctival allergen challenge.
Receives: Other: Conjunctival Allergen Challenge
Responders With EpinephrineExperimentalSubjects experienced a positive response during previous oral food challenge and required epinephrine. Will be subjected to a conjunctival allergen challenge.
Receives: Other: Conjunctival Allergen Challenge
Non-RespondersExperimentalSubjects did not experience a positive response during previous oral food challenge. Will be subjected to a conjunctival allergen challenge.
Receives: Other: Conjunctival Allergen Challenge

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ora Calibra Ocular Itching Scale

    Measured: Ten minutes after each CAC dose through duration of challenge (up to 90 minutes)

  2. Ora Calibra Ocular Hyperemia Scale

    Measured: Ten minutes after each CAC dose through duration of challenge (up to 90 minutes)

  3. Ora Calibra Itchy Palate/Mouth Scale

    Measured: Ten minutes after each CAC dose through duration of challenge (up to 90 minutes)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Oct 2018
  2. Study startMay 2016
  3. Primary completionOct 2016
  4. Study completionOct 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03693456
Sponsor's protocol ID
ORA-FA-002
Status last verified
Feb 2016
First submitted
1 Oct 2018
Last updated
3 Oct 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Conjunctival Allergen Challenge in people with Food Hypersensitivity, run by ORA, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ora Calibra Ocular Itching Scale (time frame: Ten minutes after each CAC dose through duration of challenge (up to 90 minutes)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in